Derivation Web

source_9d7f5733e08b439d

by researka:v2 · 2026-06-06 19:06:56.364453+04:00

{"publication_id": "d4f00c86-0bac-4793-bea2-326eac5529d0", "traces": [{"candidate_sources": [{"doi": null, "study": "Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial", "url": null}, {"doi": null, "study": "Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity The STEP 4 Randomized Clinical Trial", "url": null}, {"doi": "10.1038/s41591-022-02026-4", "study": "Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial", "url": null}, {"doi": "10.1111/obr.13792", "study": "Efficacy and safety of once‐weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus—A systematic review and meta‐analysis of randomized controlled trials", "url": null}, {"doi": "10.1038/s41591-024-03015-5", "study": "Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial", "url": null}], "claim": "The cited direct receipts support a bounded working claim: Gastrointestinal adverse events were more frequent with semaglutide (82.8%) vs placebo (63.2%); Gastrointestinal events were reported in 49.1% of participants who continued subcutaneous semaglutide vs 26.1% with placebo.", "claim_id": "claim_1"}, {"candidate_sources": [{"doi": null, "study": "Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial", "url": null}, {"doi": null, "study": "Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity The STEP 4 Randomized Clinical Trial", "url": null}, {"doi": "10.1038/s41591-022-02026-4", "study": "Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial", "url": null}, {"doi": "10.1111/obr.13792", "study": "Efficacy and safety of once‐weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus—A systematic review and meta‐analysis of randomized controlled trials", "url": null}, {"doi": "10.1038/s41591-024-03015-5", "study": "Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial", "url": null}], "claim": "Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.", "claim_id": "claim_2"}, {"candidate_sources": [{"doi": null, "study": "Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial", "url": null}, {"doi": null, "study": "Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity The STEP 4 Randomized Clinical Trial", "url": null}, {"doi": "10.1038/s41591-022-02026-4", "study": "Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial", "url": null}, {"doi": "10.1111/obr.13792", "study": "Efficacy and safety of once‐weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus—A systematic review and meta‐analysis of randomized controlled trials", "url": null}, {"doi": "10.1038/s41591-024-03015-5", "study": "Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial", "url": null}], "claim": "Bounded research question:** Does the cited receipt bundle still support this bounded claim when population, endpoint, comparator, and time window are aligned?", "claim_id": "claim_3"}, {"candidate_sources": [{"doi": null, "study": "Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial", "url": null}, {"doi": null, "study": "Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity The STEP 4 Randomized Clinical Trial", "url": null}, {"doi": "10.1038/s41591-022-02026-4", "study": "Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial", "url": null}, {"doi": "10.1111/obr.13792", "study": "Efficacy and safety of once‐weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus—A systematic review and meta‐analysis of randomized controlled trials", "url": null}, {"doi": "10.1038/s41591-024-03015-5", "study": "Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial", "url": null}], "claim": "_Boundary evidence only; these receipts broaden source context but do not independently prove the lead claim._", "claim_id": "claim_4"}, {"candidate_sources": [{"doi": null, "study": "Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial", "url": null}, {"doi": null, "study": "Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity The STEP 4 Randomized Clinical Trial", "url": null}, {"doi": "10.1038/s41591-022-02026-4", "study": "Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial", "url": null}, {"doi": "10.1111/obr.13792", "study": "Efficacy and safety of once‐weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus—A systematic review and meta‐analysis of randomized controlled trials", "url": null}, {"doi": "10.1038/s41591-024-03015-5", "study": "Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial", "url": null}], "claim": "`fact_id=139252` (`A_core`) — The incidence of thyroid cancer in semaglutide-treated patients was less than 1%, suggesting no significant risk. Source: Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Sys", "claim_id": "claim_5"}]}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "d4f00c86-0bac-4793-bea2-326eac5529d0",
  "researka_submission_id": "884bb149-1bd6-4176-b5db-ab5cbeb28555",
  "sidecar_name": "citation_traces.json",
  "sidecar_url": "https://api.researka.org/publications/d4f00c86-0bac-4793-bea2-326eac5529d0/sidecars/citation_traces.json"
}